Kawasaki Disease and COVID-19: Understanding the Link in Children
Comprehensive guide explaining the connection between Kawasaki disease and COVID-19, symptoms, diagnosis, treatment, and what parents should know.
Kawasaki disease (KD) is a rare but serious illness that causes inflammation in blood vessels throughout the body, primarily affecting children. Since the onset of the COVID-19 pandemic, doctors worldwide have observed an unusual rise in inflammatory illnesses resembling Kawasaki disease among children. These findings have fueled important questions about the relationship between SARS-CoV-2, the virus behind COVID-19, and pediatric inflammatory syndromes. This article explores what Kawasaki disease is, its symptoms and causes, how it may relate to COVID-19, and what this means for parents, caregivers, and healthcare professionals.
What Is Kawasaki Disease?
Kawasaki disease is an acute vasculitis, meaning it causes inflammation in the blood vessels, particularly the arteries, veins, and capillaries. It most frequently affects children under the age of five, though older children can also be impacted. The exact cause remains unknown, but it has long been suspected that viral infections may act as a trigger in genetically susceptible children. Symptoms include prolonged fever, rash, conjunctivitis, swollen lymph nodes, red lips and tongue, and skin peeling on the hands and feet.
- Prevalence: More common in children, especially those of Asian descent, but it occurs globally.
- Severity: Can cause complications if left untreated, especially involving the heart (coronary artery aneurysms).
- Treatment: Most children recover fully with early and effective treatment.
How COVID-19 May Be Linked to Kawasaki Disease
Shortly after the global outbreak of COVID-19, doctors in Europe, the United States, and elsewhere noticed clusters of children developing a rare inflammatory syndrome with alarming similarities to Kawasaki disease. This observation was most pronounced in areas experiencing high community transmission of SARS-CoV-2. The link became a research priority as clinicians saw a striking increase in hospital admissions for Kawasaki disease and a related syndrome: multisystem inflammatory syndrome in children (MIS-C).
Key Findings from Studies
- In France, a 497% increase in Kawasaki disease cases was documented during the peak of the local COVID-19 epidemic, with most affected children testing positive for SARS-CoV-2 or having confirmed exposure.
- Many children presented with symptoms that overlapped with typical Kawasaki disease, but with even higher inflammatory markers and a greater tendency for systemic involvement (such as shock or cardiac complications).
- The timing of increased Kawasaki-like illnesses has typically lagged 2–4 weeks behind peaks in COVID-19 cases, supporting the theory of a post-infectious immune reaction.
What Is Multisystem Inflammatory Syndrome in Children (MIS-C)?
MIS-C is a new, rare, but potentially serious condition that emerged alongside the COVID-19 pandemic. MIS-C shares several clinical features with Kawasaki disease. Both conditions can cause fever, rash, and inflammation of various organs, but MIS-C often involves more pronounced signs of shock, gastrointestinal symptoms, and can affect older children as well.
What others are reading
- Symptoms: Persistent fever, abdominal pain, vomiting, diarrhea, rash, bloodshot eyes, and signs of organ dysfunction.
- Overlap: Many children with MIS-C meet the diagnostic criteria for Kawasaki disease but also display additional systemic involvement.
- Risk: Children with MIS-C may require intensive care, but most recover with prompt medical intervention.
Signs and Symptoms of Kawasaki Disease
Recognizing Kawasaki disease early is crucial for effective treatment and to reduce the risk of complications. The disease typically unfolds in three phases: acute, subacute, and convalescent.
- Fever: High (usually >102°F or 39°C), lasting more than five days and not responsive to normal fever-reducing medications.
- Rash: Red, patchy, or raised rash, often starting on the trunk or groin area.
- Conjunctivitis: Redness in both eyes, typically without discharge.
- Swelling: Swollen hands and feet, sometimes with peeling skin, especially around the nails.
- Lymphadenopathy: Swollen lymph nodes in the neck (usually one side only).
- Changes in lips and mouth: Red, cracked lips, and a “strawberry tongue” (bright red, swollen tongue).
Other Possible Symptoms
- Joint pain or swelling
- Diarrhea, vomiting, or abdominal pain
- Extreme irritability (especially in infants and toddlers)
- Peeling of the skin, particularly on fingers and toes during the recovery phase
How Is Kawasaki Disease Diagnosed?
There is no single test that confirms Kawasaki disease. Diagnosis relies on a combination of clinical criteria, medical history, and exclusion of other causes. A doctor typically considers Kawasaki disease if a child has a prolonged fever plus at least four of the main symptoms listed above.
Key diagnostic steps include:
- Physical examination of the child for characteristic signs
- Blood tests to check for elevated markers of inflammation (such as C-reactive protein, ESR, white blood cell count)
- Blood tests may reveal anemia, low albumin, or abnormalities in platelets and liver enzymes
- Echocardiogram to assess heart involvement, specifically looking for coronary artery changes
- Tests to rule out other infections (including strep, enteroviruses, and SARS-CoV-2)
Differences Between Classic Kawasaki Disease and COVID-19 Associated Illnesses
| Feature | Typical Kawasaki Disease | COVID-19 Related Inflammatory Syndromes (e.g., MIS-C) |
|---|---|---|
| Average Age | Under 5 years old | Median higher, often older children and teens |
| Fever Duration | >5 days | Similar, with persistent fever common |
| Inflammatory Markers | Elevated, moderate | Markedly elevated, often higher than classic KD |
| Cardiac Involvement | Coronary artery aneurysms | Shock, myocarditis, and sometimes coronary dilation |
| Other Symptoms | Classic KD features | More organ involvement (gastrointestinal, neurological, respiratory) |
| SARS-CoV-2 Test | Negative, except rare overlap | Frequently positive, or recent household exposure |
What Causes the Connection?
The leading hypothesis is that SARS-CoV-2 acts as a trigger in susceptible children, resulting in an exaggerated immune response that targets the body’s own blood vessels and organs. This response tends to occur several weeks after the acute (initial) COVID-19 infection, rather than during the acute phase of illness. The idea is consistent with known observations that other viruses, including previous influenza pandemics and certain enteroviruses, can trigger similar surges in Kawasaki disease cases. Most researchers believe a combination of genetic, environmental, and infectious factors is involved in the pathogenesis of both KD and MIS-C.
How Common Is Kawasaki Disease and MIS-C During COVID-19?
- Even during COVID-19 surges, both Kawasaki disease and MIS-C remain rare in children compared to the total number of infected individuals.
- Critical illness from COVID-19 or inflammatory syndromes in children is still very infrequent, and most children recover fully with appropriate care.
- The majority of children with COVID-19 do not develop these severe inflammatory reactions. Risk factors remain incompletely understood but may include genetic predisposition and prior health conditions.
How Are These Conditions Treated?
Treatment for Kawasaki disease centers on reducing inflammation quickly to protect the heart and other organs. The approach for COVID-19 associated inflammatory illnesses is similar, with some additional considerations for multi-organ support.
- Intravenous immunoglobulin (IVIG): The standard first-line therapy for Kawasaki disease and MIS-C. IVIG helps dampen the abnormal immune response.
- Aspirin: Used to reduce fever, inflammation, and prevent blood clots.
- Steroids: Sometimes given when inflammation is severe or if a child is not improving with IVIG alone.
- Supportive therapies: May include fluids, medications to support blood pressure, and monitoring/treating heart complications.
- Some children with COVID-19 associated illness have required additional immunomodulatory medicines (such as infliximab or biologics) when standard therapies are insufficient.
- Follow-up: Repeat echocardiograms and ongoing monitoring to ensure the coronary arteries remain healthy.
When to Seek Medical Attention
Although both Kawasaki disease and MIS-C are rare, timely intervention is essential for recovery. Parents and caregivers should seek medical attention if a child experiences:
- High fever lasting five or more days
- Persistent rash or swelling of hands/feet
- Red, cracked lips or a red, swollen tongue
- Severe abdominal pain, vomiting, or diarrhea
- Unusual lethargy, irritability, or difficulty breathing
Prompt evaluation can help distinguish between mild common illnesses and those that require further investigation and treatment.
Can Kawasaki Disease or MIS-C Be Prevented?
At present, there is no known way to completely prevent Kawasaki disease or MIS-C since the underlying trigger involves a combination of infectious and genetic factors. However, common public health measures to reduce the spread of COVID-19, such as vaccination (for eligible age groups), hand hygiene, mask-wearing, and avoiding contact with infected individuals, may help lower risk. Recognizing symptoms early and seeking prompt care remains the most effective strategy to ensure good outcomes.
Current Research and Outlook
Doctors and scientists continue to study why some children develop Kawasaki disease or MIS-C after exposure to SARS-CoV-2, while most do not. Ongoing research is investigating:
- Whether certain genetic backgrounds confer greater susceptibility
- Optimal treatment strategies for patients with severe or resistant inflammation
- Long-term outcomes for children who develop heart involvement
- Comparison of COVID-19 associated syndromes with prior viral outbreaks that were linked to increases in Kawasaki disease incidence
Thankfully, early studies suggest that with timely diagnosis and appropriate treatment, most children make full recoveries and do not experience lasting effects. Nevertheless, ongoing vigilance is important as the pandemic continues and future variants of SARS-CoV-2 or other viruses may pose risks.
Frequently Asked Questions (FAQs)
What age group is most affected by Kawasaki disease?
Most children affected are under five years old, though older children may also develop the disease, particularly in the context of MIS-C after COVID-19 infection.
Is Kawasaki disease contagious?
No, Kawasaki disease itself is not contagious. However, the virus or infectious agent that may trigger it (e.g., SARS-CoV-2) can be spread to others.
Can COVID-19 directly cause Kawasaki disease?
Current evidence suggests SARS-CoV-2 does not directly cause Kawasaki disease but may trigger an immune-mediated response in susceptible children, leading to Kawasaki-like symptoms or MIS-C.
What are the main signs that should prompt immediate medical attention?
Fever lasting five or more days, persistent rash, red eyes, cracked lips, swelling of hands or feet, severe abdominal pain, or evidence of shock (difficulty staying awake, low blood pressure) warrant prompt evaluation by a healthcare provider.
How serious is Kawasaki disease?
Most children recover fully when treated early. Delayed or missed treatment can lead to heart complications, so prompt recognition and intervention are crucial.
Key Takeaways for Parents and Caregivers
- Kawasaki disease and COVID-19 related inflammatory syndromes are rare, but possible in children.
- Symptoms can overlap with many minor childhood illnesses, but persistent high fever, rash, and inflammation should raise suspicion.
- With proper treatment, most children make a full recovery and complications can be minimized.
- If in doubt, consult a pediatrician, especially if symptoms are severe or persist beyond a few days.
Awareness of these conditions and early action are the best defenses in protecting children’s health during COVID-19 and beyond.
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7332278/
- https://newsroom.heart.org/news/kids-with-kawasaki-disease-symptoms-possibly-linked-to-covid-19-coronavirus-infection-leading-to-critical-illness-in-children-remains-very-infrequent
- https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.1036306/full
- https://www.nature.com/articles/s41598-025-91042-8
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793496
- https://www.imperial.ac.uk/news/198077/kawasaki-like-syndrome-linked-covid-19-children-condition/
- https://www.youtube.com/watch?v=ir8MA74FDwc
Similar Articles
Read full bio of Sneha Tete
